Laurus Labs Limited

LAURUSLABS.NS | Healthcare | NSE
$983.40
+8.00 (+0.82%)

Key Metrics

Market Cap
$530.86B
P/E Ratio
76.95
EPS
$12.78
Beta
N/A
Dividend Yield
N/A
ROE
11.73%
Current Ratio
0.00

Company Information

Industry
Drug Manufacturers Specialty Generic

About Laurus Labs Limited

Laurus Labs Limited together with its subsidiaries engages in the development manufacture and sale of medicines and active pharmaceutical ingredients APIs in India and internationally The company develops manufactures and sells APIs and advanced intermediates for antiretroviral ARV antidiabetic cardiovascular proton pump inhibitors PPIs oncology gastroenterology and hepatitis C therapeutic areas It also develops and manufactures oral solid formulations for ARVs antidiabetic cardiovascular PPIs and central nervous system In addition the company provides contract development and manufacturing services for pharmaceutical companies and manufactures and sells specialty ingredients used in the nutraceutical dietary supplements and cosmeceutical products Further it develops novel enzymatic solutions for industrial biotechnology and animal origin free recombinant proteins and enzymes for biopharma and offers business support services for pharmaceutical field The company was incorporated in 2005 and is based in Hyderabad India

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-10-23 $3.60 $3.32 +8.4%
2025-07-25 $3.02 $2.05 +47.3%
2025-04-23 $4.33 $3.03 +42.9%
2025-01-22 $1.71 $1.39 +23.0%

Financial Ratios (TTM)

Gross Margin
54.64%
Operating Margin
40.59%
Net Margin
8.58%
ROA
0.00%
Price to Book
11.53
Price to Sales
8.95